Steel Therapeutics, Inc. is focused on enhancing access to compounded medications through the pursuit of FDA approval, with a particular emphasis on innovative delivery systems. Their flagship product, Fizurex™, is a single-use disposable wipe that combines nifedipine and lidocaine, which are traditionally compounded in cream form. This combination has demonstrated significant efficacy in increasing blood flow and relaxing the anal sphincter, leading to healing rates of nearly 90%. By reformulating these compounds into a more patient-friendly format, Steel Therapeutics aims to improve accessibility to this effective treatment, thereby transforming the landscape of compounded medications.

In addition to Fizurex™, Steel Therapeutics is committed to expanding its pipeline by leveraging insights gained from compounding pharmacy practices. The company is dedicated to improving the safety and accessibility of life-changing therapies, ensuring that they can be delivered at scale. With a team of experienced professionals from various sectors, including pharmacy management and medical devices, Steel Therapeutics is well-positioned to navigate the complexities of regulatory approval and clinical development, ultimately bringing innovative therapies from compounding pharmacies to patients in need.

United States

Steel Therapeutics is an Iowa-based pharmaceutical company focused on increasing access to life-changing therapies that have a track record of efficacy from compounding pharmacies.

Steel Therapeutics, Inc.

Company Details